Panacos Pharmaceuticals, Inc. engages in the discovery and development of small-molecule oral drug which is designed to treat human immunodeficiency virus and other major human viral diseases. The company is headquartered in Watertown, Massachusetts and currently employs 41 full-time employees. The firm's lead product candidate, bevirimat, is an oral HIV drug candidate in Phase II clinical testing. Panacos has dosed over 485 patients and subjects with bevirimat and have seen a good safety and tolerability profile with no indication of a relationship between adverse events and drug levels. The firm has exclusive rights from University of North Carolina at Chapel Hill (UNC) to the United States patent claiming the chemical entity bevirimat. Panacos has an exclusive worldwide license with UNC for all indications.
Follow-Up Questions
Quel est le ratio P/E de Panacos Pharmaceuticals Inc (PANC) ?
Le ratio P/E de Panacos Pharmaceuticals Inc est de 0
Qui est le CEO de Panacos Pharmaceuticals Inc ?
Dr. Alan Dunton est le President de Panacos Pharmaceuticals Inc, il a rejoint l'entreprise depuis 2007.
Quelle est la performance du prix de l'action PANC ?
Le prix actuel de PANC est de $0, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Panacos Pharmaceuticals Inc ?
Panacos Pharmaceuticals Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de Panacos Pharmaceuticals Inc ?
La capitalisation boursière actuelle de Panacos Pharmaceuticals Inc est de $0
